Latest News and Press Releases

The Phase 1/2 trial will assess the safety and clinical activity of IMC-R117C, as a monotherapy and in combination with standards of care, in patients with advanced cancers expressing PIWIL1 First...

Data from the ongoing Phase 2 of EO4010 demonstrate tumor target specific immune responses and objective tumor responses, including in liver mets, in patients with previously treated microsatellite...

AmMax Bio and MD Anderson to Advance Development of AMB-066 in Colorectal Cancer Patients with Minimal Residual Disease

ALEXANDRIA, Va., Dec. 09, 2024 (GLOBE NEWSWIRE) -- The American Academy of Physician Associates (AAPA) is proud to announce a new project, made possible through a grant from Exact Sciences, that...

Dublin, Nov. 26, 2024 (GLOBE NEWSWIRE) -- The "Asia-Pacific Radiation Oncology Market Size, Share & Trends Analysis Report by Type (External Beam Radiation Therapy, Internal Beam Radiation...

New York, United States, Nov. 21, 2024 (GLOBE NEWSWIRE) -- "Liquid biopsy" isolates and detects circulating nucleic acids (DNA or RNA), exosomes, and circulating tumor cells to diagnose primary...

Springfield, Mo., Nov. 20, 2024 (GLOBE NEWSWIRE) -- In response to the persistently high nationwide burden of colorectal cancer (CRC), Fight Colorectal Cancer (Fight CRC) has launched the Colorectal...

OSLO, Norway, Nov. 19, 2024 (GLOBE NEWSWIRE) -- On back of the MDR CE-mark for its Class IIb PolypAID™ system which the company secured in August, Augere has secured NOK 23M (USD 2.1M) for its...

Primary efficacy endpoint readout expected in mid-2025Phase 1b studies in dMMR/MSI GI tumors showed that NOUS-209 with pembrolizumab was well-tolerated, generating potent and broad immune responses...

Dublin, Nov. 14, 2024 (GLOBE NEWSWIRE) -- The "Artificial Intelligence (AI) in Oncology Market - Forecasts from 2024 to 2029" report has been added to ResearchAndMarkets.com's offering. The...